1. India Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Centenial Surgical Suture Ltd.

Centenial Surgical Suture Ltd.

BBSE:CSURGSU
71.25
INR
0.00
(0.00%)
-3.85EPS
280.37MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
139.8
141.89
141.04
144.84
144.57
153.65
152.44
101.23
121.77
144.33
140.31
146.69
147.58
150.18
Basic EPS, GAAP
4.91
5.25
4.28
4.71
4.23
5.53
3.55
2.64
1.72
2.43
3.11
-4.01
-6.04
-3.85
Free Cash Flow per Basic Share
-1.86
-0.47
-4.69
-1.82
2.87
1.55
2.74
3.1
12.59
3.11
-4.06
15.36
13.85
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
52.79
58.16
62.44
67.15
71.38
76.9
78.42
81.05
82.77
85.2
88.31
84.3
78.26
- -
Tangible Book Value per Share
52.74
58.14
62.42
67.14
71.37
76.86
78.39
81.04
82.76
85.19
88.3
84.29
78.25
- -
Basic Weighted Avg Shares
4
4
4
4
4
4
4
4
4
4
4
4
4
4
Sales/Revenue/Turnover
510
518
515
528
527
561
556
369
444
527
512
535
538
562
Operating Margin (%)
7.57
7.82
7.83
7.89
7.32
8.19
7.9
9.62
6.65
5.89
7.35
3.75
2.03
3.69
Depreciation Expense
6
8
7
6
6
7
16
16
15
13
14
43
40
40
Net Income, GAAP
18
19
16
17
15
20
13
10
6
9
11
-15
-22
-14
Effective Tax Rate (%)
33.84
33.99
34.17
32.54
36.09
29.04
39.87
37.13
41.64
39.44
10.89
- -
- -
- -
Profit Margin (%)
3.51
3.7
3.03
3.25
2.92
3.6
2.33
2.6
1.41
1.68
2.22
-2.74
-4.09
-2.57
Working Capital
183
200
220
234
248
261
270
291
291
303
325
311
285
- -
LT Debt
22
12
12
12
12
12
79
69
50
44
123
204
- -
- -
Total Equity
193
212
228
245
260
281
286
296
302
311
322
308
286
- -
Return on Invested Capital (%)
5.9
5.98
4.5
4.55
6.14
7.97
5.88
4.56
3.64
4.11
6.32
- -
- -
- -
Return on Capital (%)
7.75
8.49
7.04
5
4.23
5.35
4.28
3.21
2.27
2.87
3.7
- -
- -
- -
Return on Common Equity (%)
9.75
9.46
7.09
7.27
6.1
7.45
4.57
3.31
2.1
2.89
3.58
-4.65
-7.43
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
107
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
375
278
280

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
600
- -
Cash, Cash Equivalents & STI
- -
2
- -
Accounts Receivable, Net
- -
183
- -
Inventories
- -
406
- -
Total Current Liabilities
- -
316
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
107
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.39%
-0.6%
-7.17%
Free Cash Flow
-76.24%
-97.53%
-9.88%
Net Income, GAAP
-17.48%
-28.78%
50.62%
Sales/Revenue/Turnover
1.56%
8.24%
0.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
137
143
122
133
535
2026
129
135
149
126
538
2027
153
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.82
0.35
-2.3
-3.24
-4.01
2026
-0.11
-0.03
0.4
-6.34
-6.04
2027
2.01
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Vijay Kalidas Majrekar
Full Time Employees
266
Sector
Health technology
Industry
Medical specialties
Address
F-29, MIDC Thane MA India 421401
IPO Date
Sep 16, 2005
Website
centenialindia.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Centenial Surgical Suture Limited Centenial Surgical Suture Limited (CSURGSU.BO), an India-based medical device company, engages in the development, manufacturing, and supply of surgical sutures and related medical devices primarily for surgical applications. The company offers absorbable sutures including catgut, centicryl, centicryl rapid, centisorb, centisorb rapid, centisorb tri-plus, centisynth, and monosynth; non-absorbable sutures such as centibond, centidene, centilene, centisilk, centlon, and centsteel; superior atraumatic needles comprising CV needles, excel point needles, general surgery needles, surepoint needles, and vision black needles; cardiovascular sutures like centibond, centiiwax, centilene, and centsteel; and other medical devices that include centipunch, centcel, centiitape, centiiwax, centilene mesh, centipace, centipled, disposable surgical skin stapler, temporary pacemaker electrodes, female urinary incontinency sets, and titanium haemostatic clips. Incorporated in 1995 and headquartered in Thane, Maharashtra, India, with manufacturing facilities in Murbad, the company operates mainly in India and internationally, adhering to ISO 13485:2016, ISO 9001:2015, ISO 45001:2018, WHO GMP, and CE standards. Recent developments include reporting a rise in first-quarter 2024 earnings with revenues of INR 137.37 million; appointing Akash Modi and Ridhima Limaye as additional independent non-executive directors in 2024; re-appointing key executives including the managing director and chief executive officer and whole-time directors; and appointing a new internal auditor, alongside scheduling board meetings for strategic considerations as of August 2025.